Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | CCNC | P24863 | 1/20 | 0.38 |
| ▸ | CDK8 | P49336 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.36 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4367036 | 1.00 | SIRT2 (0.40) | SIRT2ALDH1A1MAPTDRD2CCNC | |
| SCHEMBL13623226 | 0.92 | SIRT2 (0.40) | SIRT2ALDH1A1MAPTDRD2CCNC | |
| SCHEMBL13623216 | 0.85 | ALDH1A1 (0.52) | ALDH1A1MAPTPOLBKMT2AHTT | |
| SCHEMBL13623213 | 0.84 | MAPT (0.46) | SIRT2ALDH1A1MAPTPOLBKMT2A | |
| SCHEMBL1028056 | 0.82 | MMP1 (0.37) | SIRT2ALDH1A1DRD2POLBKMT2A | |
| SCHEMBL1028055 | 0.82 | MMP1 (0.37) | SIRT2ALDH1A1DRD2POLBKMT2A | |
| SCHEMBL12836001 | 0.79 | LMNA (0.54) | ALDH1A1MAPTDRD2KMT2AHTT | |
| SCHEMBL13622511 | 0.77 | MMP1 (0.45) | SIRT2ALDH1A1MAPTPKMPOLB | |
| SCHEMBL1026372 | 0.77 | LMNA (0.40) | SIRT2ALDH1A1MAPTPOLBKMT2A | |
| SCHEMBL1025542 | 0.77 | MAPT (0.42) | SIRT2ALDH1A1MAPTPKMPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8871753-B2 | Macrocyclic compounds and their use as kinase inhibitors | INCYTE CORPORATION (US) | 2014-10-28 | — | — | US | disclosed |
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | JAK2, JAK1, ALK | SIRT2 4221/4885ALDH1A1 2511/4885MAPT 3239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.